<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949802</url>
  </required_header>
  <id_info>
    <org_study_id>VIA-001</org_study_id>
    <nct_id>NCT04949802</nct_id>
  </id_info>
  <brief_title>Glaucoma Surgery Using the ViaLase Femtosecond Laser</brief_title>
  <official_title>A Prospective Single Center Clinical Study for Femtosecond Laser Glaucoma Surgery Using the ViaLase Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vialase, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vialase, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-center, multi-cohort clinical trial of ViaLase Laser for the reduction of&#xD;
      IOP in patients with open angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of study is to obtain initial evidence of safety of femtosecond laser glaucoma&#xD;
      surgery using the ViaLase Laser for the treatment of open angle glaucoma. The ViaLase Laser&#xD;
      System is intended to create apertures through the trabecular meshwork to reduce intraocular&#xD;
      pressure in patients with open angle glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multi-cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>continuous</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of eyes &gt;=20% reduction</measure>
    <time_frame>6 months</time_frame>
    <description>binary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes &lt;=20 mmHg</measure>
    <time_frame>6 months</time_frame>
    <description>binary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes &lt;=18 mmHg</measure>
    <time_frame>6 months</time_frame>
    <description>binary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with Vialase laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vialase laser</intervention_name>
    <description>create an aperture through the trabecular meshwork</description>
    <arm_group_label>laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of open-angle glaucoma (OAG) (including pigmentary, pseudoexfoliative or&#xD;
             refractory glaucoma) or ocular hypertension (OHT).&#xD;
&#xD;
          2. For OAG:&#xD;
&#xD;
             Glaucomatous visual field defects or optic nerve defects and defined as one or more of&#xD;
             the following:&#xD;
&#xD;
               1. A cluster of 3 or more points in an expected location of the visual field&#xD;
                  depressed below the 5% level, at least 1 of which is depressed below the 1% level&#xD;
                  on the pattern deviation (PD) plot; or&#xD;
&#xD;
               2. Glaucoma hemi-field test &quot;outside normal limits&quot; Note: Visual field reliability&#xD;
                  indices (i.e., fixation losses, false positives, and false negatives) should all&#xD;
                  be less than 33%. For subjects with a screening visual acuity of 20/100 or worse,&#xD;
                  a visual field is not required, and the above criteria do not need to be met.&#xD;
&#xD;
             OR&#xD;
&#xD;
             Nerve abnormality characteristic of glaucoma as evaluated by clinical ophthalmoscopy&#xD;
             defined as one or more of the following:&#xD;
&#xD;
               1. Diffuse thinning, focal narrowing or notching of the optic disc rim especially at&#xD;
                  inferior or superior poles.&#xD;
&#xD;
               2. Localized abnormalities of the peripapillary retinal nerve fiber layer,&#xD;
                  especially at inferior or superior poles.&#xD;
&#xD;
               3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural&#xD;
                  tissue.&#xD;
&#xD;
             For OHT: Diagnosis based on the investigator's evaluation.&#xD;
&#xD;
          3. Subject eye is phakic or pseudophakic:&#xD;
&#xD;
               1. If phakic, then the crystalline lens will not have visually significant cataract&#xD;
                  that is expected to require cataract surgery within next one year. Cataract will&#xD;
                  be evaluated by the clinician subjectively.&#xD;
&#xD;
               2. If pseudophakic, then a posterior chamber IOL in the capsular bag is present. A&#xD;
                  minimum of 60 days is required between cataract surgery and study screening.&#xD;
                  Anterior chamber intraocular lens (IOL), iris fixed IOL, or implantable contact&#xD;
                  lens (ICL) will be excluded.&#xD;
&#xD;
          4. Mean IOP with medication at screening between 12 mmHg and 26 mmHg, inclusive, on up to&#xD;
             4 ocular hypotensive medications with stable regimen for 2 months before screening OR&#xD;
             an IOP of 22 to 36 mmHg on 0 (zero) ocular hypotensive medications.&#xD;
&#xD;
          5. At baseline, unmedicated IOP of 20 to 36 mmHg for OAG subjects who are washed-out; 22&#xD;
             to 36 mmHg for OHT subjects on no medications. Note: For subjects with refractory&#xD;
             glaucoma (prior failed incisional or cilioablative glaucoma surgeries or uncontrolled&#xD;
             IOP with maximum tolerated ocular hypotensive medications), washout is not required.&#xD;
&#xD;
          6. Iridocorneal angle anatomy defined as follows:&#xD;
&#xD;
               1. Trabecular meshwork visible on gonioscopy defined by Shaffer grade ≥ 3.&#xD;
&#xD;
               2. Normal anatomy as determined by gonioscopy.&#xD;
&#xD;
          7. Corrected visual acuity of 20/200 or better in the study eye. The non-study eye must&#xD;
             have hand motion or better vision.&#xD;
&#xD;
          8. Age 35 years or older&#xD;
&#xD;
          9. If the subject is using anticoagulants, the subject is willing and able to temporarily&#xD;
             discontinue using anticoagulant medications 3 days prior to laser procedure. Subject&#xD;
             will resume anticoagulant medications post-procedure.&#xD;
&#xD;
         10. Available, willing, with sufficient cognitive awareness to comply with examination&#xD;
             procedures and schedules.&#xD;
&#xD;
         11. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Previous glaucoma surgeries including stent implantation or other laser surgeries on&#xD;
             study eye. Note: in case of refractory glaucoma subjects, prior failed incisional or&#xD;
             cilioablative surgeries for glaucoma are acceptable.&#xD;
&#xD;
          2. Prior intraocular surgery except cataract surgery per inclusion criteria #3.&#xD;
&#xD;
          3. Pseudophakic eyes with an anterior chamber intraocular lens (IOL), iris fixed IOL, or&#xD;
             implantable contact lens (ICL).&#xD;
&#xD;
          4. Cup: Disc (C:D) ratio ≥ 0.8.&#xD;
&#xD;
          5. Glaucoma types as follows:&#xD;
&#xD;
               1. Traumatic, uveitic, neovascular, or angle-closure.&#xD;
&#xD;
               2. Glaucoma associated with vascular disorders.&#xD;
&#xD;
          6. Corneal status as follows:&#xD;
&#xD;
               1. Any condition that would preclude safe participation in the study or reliable IOP&#xD;
                  assessments including active inflammation, edema, keratitis,&#xD;
                  keratoconjunctivitis, keratouveitis.&#xD;
&#xD;
               2. Clinically significant dystrophy such as bullous keratopathy or Fuch's dystrophy.&#xD;
&#xD;
               3. Guttata that would preclude safe participation in the study or reliable study&#xD;
                  assessments.&#xD;
&#xD;
               4. Anticipated surgery of any type (including LASIK, LASEK, PRK, cataract, etc.)&#xD;
                  during the study that may alter IOP measurement.&#xD;
&#xD;
               5. Corneal opacities or disorders that would inhibit visualization of the angle&#xD;
                  (such as severe arcus senilis).&#xD;
&#xD;
               6. Central corneal thickness less than 440 microns or greater than 620 microns.&#xD;
&#xD;
          7. Choroid status as follows:&#xD;
&#xD;
               1. Choroidal detachment&#xD;
&#xD;
               2. Effusion&#xD;
&#xD;
               3. Choroiditis&#xD;
&#xD;
               4. Neovascularization&#xD;
&#xD;
               5. Any active choroidopathy.&#xD;
&#xD;
          8. Retinal or optic nerve disorders, either degenerative or evolutive, that are not&#xD;
             associated with the existing glaucoma condition including: proliferative diabetic&#xD;
             retinopathy, central retinal artery occlusion, central retinal vein occlusion, wet&#xD;
             age-related macular degeneration, dry age-related macular degeneration (e. g.,&#xD;
             presence of numerous large drusen associated with disturbance to or elevation of the&#xD;
             retinal pigment epithelium), significant retinal pigment epithelial changes or optic&#xD;
             atrophy, pathological myopia, red disease.&#xD;
&#xD;
             Note: Minor diabetic retinopathy or hypertensive retinopathy are permitted.&#xD;
&#xD;
          9. Elevated episcleral venous pressure associated with:&#xD;
&#xD;
               1. Active thyroid orbitopathy.&#xD;
&#xD;
               2. Cavernous sinus fistula.&#xD;
&#xD;
               3. Sturge-Weber syndrome.&#xD;
&#xD;
               4. Orbital tumors.&#xD;
&#xD;
               5. Orbital congestive disease.&#xD;
&#xD;
         10. Other ocular conditions as follows:&#xD;
&#xD;
               1. Sequelae from trauma that would preclude safe participation in the study or&#xD;
                  reliable study assessments (e.g., chemical burns, blunt trauma, etc.)&#xD;
&#xD;
               2. Chronic ocular inflammatory disease or presence of active ocular inflammation or&#xD;
                  infection (e.g., uveitis, iritis, iridocyclitis, retinitis)&#xD;
&#xD;
               3. Any pathology for which, in the investigator's judgement, the following would be&#xD;
                  either at risk or contraindicated:&#xD;
&#xD;
             i. Compliance to elements of the study protocol (e.g., ophthalmic examinations,&#xD;
             follow- up visits) ii. Subjects with inadequate space in the anterior chamber and/or&#xD;
             angle as determined by slit lamp examination and gonioscopy.&#xD;
&#xD;
         11. Subject status as follows:&#xD;
&#xD;
               1. Uncontrolled systemic disease (e.g., diabetes, hypertension) that could&#xD;
                  compromise their participation in the study.&#xD;
&#xD;
               2. Use of systemic medications (either current, within 30 calendar days of screening&#xD;
                  exam, or anticipated) that may cause an increase in IOP, (e.g., systemic steroids&#xD;
                  including oral or IV formulation, topical steroids applied on the periorbital&#xD;
                  surface within ¼&quot; of the external lid margins and oral inhaled steroids). Nasal&#xD;
                  inhaled steroids are allowed.&#xD;
&#xD;
               3. Active concurrent enrollment in any investigational trial or previous&#xD;
                  participation in any investigational trial within 30 days of the screening exam.&#xD;
&#xD;
               4. Women who are nursing, are pregnant or are of childbearing potential who refuse&#xD;
                  to use reliable contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melvin Sarayba, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vialase, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kinga Kranitz, MD</last_name>
    <phone>36-20-8258468</phone>
    <email>kranitzkinga@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zoltan Nagy, MD</last_name>
    <phone>36-20-8258468</phone>
    <email>zoltan.nagy100@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Semmeweis University Ophthalmology Clinic</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kinga Kranitz, MD</last_name>
      <phone>36-20-8258468</phone>
      <email>kranitzkinga@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zoltan Nagy, MD</last_name>
      <phone>36-20-8258468</phone>
      <email>zoltan.nagy100@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zoltan Nagy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

